DOSAGE INDEX / SINGLE
CJC-1295 NO DAC
Research, reported schedules and supply planning.
Understand why CJC-1295 No DAC requires an exact molecular match before borrowing long-acting hormone findings, duration claims or clinical conclusions.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 100–300 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
DAC and no-DAC entries are different preparations and must not be substituted.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- FDA's 2024 scientific briefing distinguishes CJC-1295 and CJC-1295 DAC as different active moieties. That distinction matters when a product labeled No DAC cites research on long-acting CJC-1295. The names do not make the materials interchangeable. [1]
- A 2006 study examined long-acting CJC-1295 in healthy adults and reported sustained increases in GH and IGF-I. It studied that preparation's pharmacology, not a product identified only as No DAC. [2]
- A separate 2006 study of long-acting CJC-1295 found preserved GH pulsatility alongside increased basal secretion. It did not test an unspecified No DAC product. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 16 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- FDA identity discussion
- Original study
- Original secretion study
- WikipediaFurther reading · Listed in reference bibliography.
- American Journal of Physiology (2006)Further reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.